Roche Hopes To Gain Broad Market For Tecentriq In Adjuvant NSCLC
Interim ASCO Data Show Improvement in PD-L1 Expressors, All-Comers
An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.
You may also be interested in...
The data illustrate the growing importance of adjuvant settings of solid tumors for PD-1/PD-L1 inhibitors, which could make up more than one-quarter of their sales in 2025.
Public Company Edition: There was just one initial public offering during the past two weeks, but another biotech-focused SPAC went public and Gingko Bioworks announced a high-value SPAC merger. Also, Insmed and Dynavax offerings led recent public company financings.
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.